Physician profile
Simon Szuster
NPI 1548967847
$6,542.66
in general payments reported to CMS, 2019-2025
16 companies · $2,440 in 2025
The $2,440 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,471 · 2024: $2,631 · 2025: $2,440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,494 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,493.82 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,756.34 | 2023-2025 | Caplyta |
| Alkermes, INC. | $1,278.37 | 2023-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $939.25 | 2023-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Abbvie INC. | $806.64 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $549.39 | 2023-2025 | Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $213.93 | 2023-2025 | Spravato, Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $187.48 | 2025 | Cobenfy |
| Lundbeck LLC | $184.13 | 2023-2025 | Abilify Maintena, Rexulti |
| Corium, LLC | $167.98 | 2023-2024 | Azstarys |
| Axsome Therapeutics, INC. | $147.58 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $89.61 | 2023-2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $67.79 | 2023-2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $56.64 | 2023 | Hetlioz, Fanapt |
| Biogen, INC. | $53.62 | 2024 | |
| Collegium Pharmaceutical, INC. | $24.08 | 2025 | Jornay Pm |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $19.83 | 2024 | Xelstrym, Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Szuster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.